Clinical trials of CAR-T cells in China

Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric antigen receptor (CAR)-engineered T cells are widely studied for cancer immunotherapy. CD19-specific CAR-T cells, tisagenlecleucel, have been recently approved for clinical application....

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Bingshan, Song, Yongping, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651613/
https://www.ncbi.nlm.nih.gov/pubmed/29058636
http://dx.doi.org/10.1186/s13045-017-0535-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651613/
https://www.ncbi.nlm.nih.gov/pubmed/29058636
http://dx.doi.org/10.1186/s13045-017-0535-7

Ejemplares similares